All interventional cardiologists must be able to perform a pericardiocentesis. Whether we deal with a chronic total occlusion, a supposedly simple coronary angioplasty (we all have witnessed the perforation of a supposedly risk-free coronary artery), or a transcatheter aortic valve replacement (whose rise gave us another significant source of tamponades), we must all be ready<a href="https://solaci.org/en/2018/04/25/constrictive-pericarditis-after-pericardiocentesis/" title="Read more" >...</a>
Delayed coronary obstruction (after TAVR, outside the cath lab) is a rare complication with high mortality rates, not unlike acute obstruction. Cardiologists should be expectant and, upon the slightest suspicion of this complication, patients should be brought back to the cath lab for a coronary angiography. Occlusion immediately after implant release has been well-studied and<a href="https://solaci.org/en/2018/04/11/delayed-coronary-obstruction-after-tavr-a-complication-we-had-not-considered/" title="Read more" >...</a>
Using instantaneous wave-free ratio (iFR) to guide decisions on revascularization of intermediate lesions is cheaper than using fractional flow reserve (FFR). Based on costs from the DEFINE-FLAIR trial, researchers estimate the difference to be almost USD 1000. This should not be seen as good news for any given technology (iFR, in this case), but for physiologic<a href="https://solaci.org/en/2018/04/05/acc-2018-define-flair-sub-analysis-ifr-more-comfortable-faster-and-much-cheaper/" title="Read more" >...</a>
Since the last version of the European guidelines on the diagnosis and treatment of peripheral arterial disease in 2011, there have been many trials and registries that warrant guideline adjustments in many aspects. The first novelty is the teamwork that gave way to these guidelines, which were written in collaboration with the European Society of<a href="https://solaci.org/en/2018/04/04/whats-new-in-the-european-guidelines-on-peripheral-arterial-disease/" title="Read more" >...</a>
Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events at the expense of increased bleeding. This is an affordable cost, and the net clinical benefit supports these new antiplatelet therapies. The one-year follow-up of the PRAGUE-18 study focused on a comparison of efficacy and safety between prasugrel<a href="https://solaci.org/en/2018/03/07/what-is-the-best-antiplatelet-therapy-in-primary-angioplasty-at-12-months/" title="Read more" >...</a>
The last issue of ProEducar, SOLACI’s newsletter for fellows in training, focuses on a relevant and complex topic of interest: Congenital Heart Disease. Find clinical cases, step by step techniques, interviews to experts and thorough analyzes carried out by prestigious Latin American experts, in this stimulating and detailed bulletin designed for the continuous training of<a href="https://solaci.org/en/2018/02/07/proeducar-110-on-congenital-heart-disease-has-been-released/" title="Read more" >...</a>
1) The 10 Commandments of ESC’s New STEMI Guidelines The authors have given an entertaining account of the most relevant points and differences between the new STEMI guidelines and the prior ones, from 2014. Read more 2) Burnout Syndrome among Cardiologists For the first time, the American College of Cardiology (ACC) has carried out a survey on this phenomenon,<a href="https://solaci.org/en/2018/02/01/these-were-the-5-most-read-scientific-articles-of-january/" title="Read more" >...</a>
1) New High Blood Pressure Guidelines The wait is finally over: the high blood pressure guidelines that have been in the works for the past 3 years saw the light of day at the American Heart Association (AHA) 2017 Scientific Sessions. Read more 2) Nearly half of interventional cardiologists may have pre-cataract lesions This statement is based on eye<a href="https://solaci.org/en/2018/01/23/the-9-most-read-scientific-articles-of-2017-in-interventional-cardiology/" title="Read more" >...</a>
From August 1st to 3rd | SOLACI-SOCIME 2018 Congress As usual, SOLACI will carry out the largest Interventional Cardiology event in Latin America. This congress, organized alongside the Mexican Interventional Cardiology Society (SOCIME), will feature world-renowned international guests, scientific sessions held jointly with the most important international associations, live cases, and the Pro-Educar pre-congress learning<a href="https://solaci.org/en/2018/01/17/2018-solaci-calendar-of-events/" title="Read more" >...</a>
1) On Radiation Protection: Editorial comment by Dr. Ariel Durán I am pleased to witness the increased amount of scientific papers in high impact journals addressing topics related to radiation protection or the harmful effects of radiation on our patients and primary or secondary operators. Similarly, it is my pleasure to see that SOLACI has<a href="https://solaci.org/en/2018/01/09/radioprotection-6-essential-articles-to-keep-you-updated/" title="Read more" >...</a>